Opella Invests MXN 1.2 Billion in Mexico to Strengthen Pharmaceutical Manufacturing

The pharmaceutical industry continues to view Mexico as a strategic manufacturing hub for Latin America. Opella, a global company specializing in self-care products, inaugurated a new Enterogermina production line at its plant in Ocoyoacac, State of Mexico. Backed by an investment of MXN 1.2 billion, the project will strengthen the company’s advanced manufacturing capabilities, increase domestic production, and expand its export platform across the region.

The new facility will be able to produce 200 million mini bottles of liquid Enterogermina annually, one of the probiotics with the strongest presence in the Mexican market. In addition to increasing production capacity, the project incorporates technology transfer and manufacturing processes that meet international standards, reinforcing Mexico’s role within the company’s global production network.

“Opella’s purpose is to put health in the hands of more people through trusted products and clear, accessible information. This investment significantly strengthens our manufacturing and innovation capabilities, allowing us to bring effective self-care solutions to more families in Mexico and other countries,” said Luis Soares, General Manager of Opella Mexico.

Mexico Increases Its Share of Opella’s Pharmaceutical Manufacturing

With the launch of this new production line, Opella will increase the proportion of products for the Mexican market that are manufactured in the country from 60% to 80%, while also expanding its capacity to supply other markets throughout Latin America.

Production will begin gradually as the regulatory and validation processes are completed, as part of a long-term strategy to establish Mexico as one of the company’s leading manufacturing hubs.

The investment is part of a MXN 2.3 billion plan aimed at strengthening Opella’s industrial infrastructure in Mexico.

“This new production line and our investment plans reflect Opella’s confidence in Mexico, its talent, and its capabilities for developing advanced pharmaceutical manufacturing. Mexico is a key platform within our global network, and this expansion confirms its importance to the company’s future growth,” said Rafik Amrane, Global Head of Supply Chain at Opella.

The Expansion Will Create Jobs and Strengthen the Pharmaceutical Industry

The inauguration was attended by federal and state authorities, as well as representatives of the government of France, including Ambassador Delphine Borione. She emphasized that the investment aligns with the objectives of Plan Mexico, which seeks to strengthen industrial capabilities and promote innovation in the healthcare sector.

The ambassador stated that the project will contribute to the creation of 50 direct jobs and 450 indirect jobs, while strengthening the State of Mexico’s industrial ecosystem and positioning the country as a regional leader in pharmaceutical manufacturing.

The expansion also incorporates the environmental strategy of the Ocoyoacac plant, which currently operates using 100% clean energy supplied by wind farms and a system of 270 solar panels.

Since 2019, the facility has reduced its carbon dioxide emissions by 80%, decreased water consumption by 39%, eliminated the disposal of waste in landfills, and achieved a 94% cardboard recycling rate.